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1. Introduction 
Inflammatory bowel disease (IBD) is a chronic condition which is characterized by recurrent 
immune-mediated inflammation of the gastrointestinal system. IBD is frequently associated 
with extraintestinal manifestations (EIM) characterized by involvement of multiple organs.  
EIM occur in 21% to 47% of IBD patients (Navaneethan & Shen, 2010). While some 
extraintestinal manifestations are encountered more frequently in Crohn’s disease (CD) than 
in ulcerative colitis (UC), some are encountered equally in CD and UC. While the degree of 
involvement of the  skin, eyes, and joints is parallel to disease activity,  hepatobiliary and 
pulmonary involvement is independent of disease activity and intestinal inflammation 
(Greenstein AJ, et al., 1996). 
Hepatopancreatobiliary (HPB) manifestations are the most frequently encountered EIM in 
patients with IBD. They can be encountered in various ways: 
1. HPB conditions sharing the same pathological mechanisms with IBD (Primary 
Sclerosing Cholangitis (PSC), small-duct PSC/pericholangitis, and PSC/autoimmune 
hepatitis overlap,  IBD associated acute or chronic idiopathic pancreatitis) 
2. HPB conditions that reflect the degree of pathophysiologic damage seen in IBD 
(Cholelithiasis and portal vein thrombosis) 
3. HPB conditions related to side effects of drugs used in treatment of IBD (Drug induced 
or associated hepatitis, pancreatitis, cirrhosis, Hepatitis B reactivation, hepatosplenic T 
cell lymphoma) 
4. HPB conditions possibly related to IBD (Autoimmune pancreatitis, IgG4-associated 
cholangitis,  fatty liver, hepatic amiloidosis, granulomatous hepatitis, primary biliary 
cirrhosis) (Navaneethan & Shen, 2010)   
The various HPB manifestations and their associations are summarized in Tables 1 and 2. 
The aim of this chapter is to cover in detail primary sclerosing cholangitis, which is an 
important and frequently encountered HPB manifestation of ulcerative colitis.  
2. The association of Inflammatory Bowel Disease and Primary Sclerosing 
Cholangitis 
PSC is a chronic cholestatic hepatobiliary disease that often develops in the setting of IBD 
and which affects predominantly young to middle-aged  patients (Olsson et al., 1991). 
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HBP manifestations with a possibly 
shared pathogenesis and mechanism as 
IBD 
Primary sclerosing cholangitis(PSC) 
Small- duct PSC 
Cholangiocarcinoma 
Autoimmune hepatitis/PSC overlap 
IgG4 associated cholangitis 
Acute and chronic idiopathic pancreatitis 
HPB manifestations parallel the 
pathophysiology associated with IBD
Gallstones
Portal vein thrombosis and hepatic abscess 
HPB manifestations associated with 
treatment of IBD 
Drug induced hepatitis(azathioprine, 6-
mercaptopurine, methotrexate, cyclosporine, 
infliximab) 
Reactivation of hepatitis B(infliximab) 
Drug induced pancreatitis(azathioprine, 6-
mercaptopurine), Hepatosplenic T-cell 
lymphoma
HPB manifestations possibly associated 
with IBD 
Fatty liver
Hepatic amyloidosis 
Granulomatous hepatitis 
Primary biliary cirrhosis 
Autoimmune pancreatitis 
Table 1. Association Between Inflammatory Bowel Disease (IBD) and 
Hepatopancreatobiliary (HPB) Manifestations. Adapted from Navaneethan & Shen, 2010 
 
HPB manifestation Ulcerative Colitis Crohn’s Disease 
Primary sclerosing cholangitis(PSC) ++ +(colonic or ileocolonic) 
Small duct PSC ++ + 
Cholangiocarcinoma ++ + 
Autoimmunehepatitis/PSC overlap ++ + 
IgG4- associated cholangitis ++ + 
Acute and chronic pancreatitis + ++ 
Gall stones - ++ 
Portal vein thrombosis and hepatic abscess + ++ 
Drug induced hepatitis ++ ++ 
Reactivation of hepatitis B(infliximab) ++ ++ 
Drug induced pancreatitis + ++ 
Hepatosplenic T-cell lymphoma +/- + 
Autoimmune pancreatitis ++ + 
Fatty liver ++ ++ 
Hepatic amyloidosis - ++ 
Granulomatous hepatitis - ++ 
Primary biliary cirrhosis ++ + 
Table 2. HPB Manifestations Associated with IBD. Adapted from Navaneethan & Shen, 2010 
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The association of primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) was first 
reported by Smith and Loe in 1965 (Smith&Loe, 1965).  The incidence of IBD in patients with 
PSC is 25-30%. Increasing awareness of association of PSC and UC led to more widespread 
use of endoscopic retrograde cholangiopancreatography (ERCP) and hence more cases were 
diagnosed with PSC (Broome & Bergquist, 2006). 
The association of PSC and Crohn’s disease, which was first described by Atkinson and 
Carroll in 1964 (Atkinson & Carroll, 1964) , is relatively rare. The incidence of CD in PSC 
varies between 1.3-14% (Wiesner & LaRusso, 1980; Chapman et al., 1980; Rasmussen et al., 
1997; McGarity et al., 1991; Faubion et al., 2001; Loftus et al., 2005; Tobias et al., 1983).  The 
most eminent finding is rectal sparing. Colonic stricture and perianastomotic ulcers are 
relatively rare in this patient group. Patients with PSC and CD almost always have extensive 
colitis or ileocolitis, but never have isolated ileitis (Broome & Bergquist, 2006).   
About 85-90% of patients with PSC and IBD are comprised of UC patients and the 
remainder are comprised of patients with Crohn’s colitis or Crohn’s ileocolitis (Olsson et al., 
1991).  
IBD can be diagnosed at any time throughout the course of PSC, and PSC can develop at 
any time throughout the course of IBD ( Fausa  et al., 1991; Broome  et al., 1990). However, 
IBD is often diagnosed many years before the diagnosis of PSC.  PSC can occur many years 
after proctocolectomy for colitis; IBD can be diagnosed many years after liver 
transplantation for advanced PSC ( Fausa et al., 1991; Wiesner & LaRusso, 1980; Aadland et 
al., 1987; Chapman et al., 1980; Riley  et al., 1997) . As IBD and PSC can be asymptomatic, the 
time of diagnosis depends on the diagnostic alertness of the physician (Broome & Bergquist, 
2006).   
PSC has a variable natural course. Nevertheless, PSC is typically characterized by 
progressive inflammation, obliterative fibrosis, damage to the intrahepatic and extrahepatic 
biliary tree and eventually biliary fibrosis, cirrhosis and finally liver failure. PSC is often 
diagnosed between the 3rd  and 5th decades and male to female gender ratio is 2:1 (Chapman 
et al., 1980; Lee & Kaplan, 1995; Navaneethan & Shen, 2010) . Freeman  et al. observed that 
patients with PSC had more extensive endoscopic and histological inflammation of the 
afferent limb who had restorative proctocolectomy with ileal pouch-anal anastomosis 
(IPAA) for UC than those with no concurrent PSC (Freeman et al., 2008). 
A report from Mayo Clinic has identified characteristic clinical, endoscopic, and histological 
findings in IBD accompanied by PSC as quiescent colitis, substantial preclinical phase, 
pancolitis, rectal sparing, backwash ileitis, pouchitis, and colorectal dysplasia/carcinoma 
(Loftus et al., 2005) (Table 3). 
 
Clinical, Endoscopic, and Histological Findings that Characterize IBD-PSC 
Quiescent colitis 
Substantial preclinical phase 
Pancolitis 
Rectal sparing 
Backwash ileitis 
Pouchitis 
Colorectal dysplasia/carcinoma 
Table 3. Clinical, Endoscopic, and Histological Findings that Characterize IBD-PSC.  
Adapted from Broome & Bergquist, 2006 
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2.1 Prevalence of IBD in patients with PSC 
The prevalence of UC in patients with PSC varies from country to country in the range of 21-
80% (Takikawa & Manabe, 1997; Bergquist A et al., 2002). The prevalence of PSC in patients 
with Crohn’s disease varies between 1.4-3.4% (Rasmussen et al., 1997; Schrumpf et al., 1980; 
Shepherd et al., 1983). Colitis in PSC is often quiescent or mild. Therefore, all patients with 
PSC should undergo colonoscopy and multiple biopsies should be taken to estimate the true 
prevalence (Broome & Bergquist, 2006). An algorithm for screening for IBD in patients with 
PSC is given in Figure 1. 
 
 
Fig. 1. Screening for IBD in patients with PSC. 
Adapted from Navaneethan U, Shen B, 2010, and Broome U, Bergquist A, 2006 
2.2 Prevalence of PSC in patients with IBD 
The prevalence of PSC in patients with IBD and persistently abnormal liver function tests is 
2.4-7.5% (Olson R, et al., 1991; Aadland E et al., 1987). PSC prevalence is 5.5 % in patients 
with substantial colitis, and 0.5% in patients with distal colitis (Olsson et al., 1991). 1.3 to 
14% of  patients with Crohn’s disease have PSC (Wiesner &LaRusso 1980; Chapman et al., 
1980; Rasmussen et al 1997; McGarity et al., 1991; Faubion et al., 2001; Loftus et al., 2005). 
PSC can present as an asymptomatic disease characterized by mild increases in 
aminotransferases, episodes of normal liver function tests can also occur.  The frequency of 
liver function test screening is decisive in determining the prevalence of this disease. 
However, there may also be liver enzyme elevations due to autoimmune hepatitis, fatty 
liver, colonic disease activation, total parenteral nutrition and steroid use (Loftus et al., 1997; 
Broome et al., 1994). Therefore, liver function tests at presentation may be misguiding. 
Ideally, liver function tests must be assessed when the colonic disease is in the inactive 
phase (Broome & Bergquist, 2006). An algorithm for PSC screening in a patient with IBD is 
presented below in Figure 2. 
Enlargement of perihepatic lymph nodes is a common finding in PSC (Outwater et al., 1992). 
The presence of enlarged perihepatic lymph nodes in a patient with UC should alert the 
Presence of IBD at diagnosis of PBC 
Perform a colonoscopy with mulple 
biopsies 
Treatment with ursodeoxycholic acid, 5-
ASA/sulphasalazine. 
Annual colonoscopic surveilliance 
IBD 
No evidence of IBD 
Screening 
colonoscopy ıf the 
symptom occurs 
Dysplasia 
No dysplasia 
Consider 
colectomy 
Connue annual 
endoscopic 
surveillence 
Yes No 
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clinician for PSC. A prospective study by Hirche et al  that involved 310 IBD  patients showed 
that the detection of enlarged perihepatic lymph nodes by ultrasonography (US) was a better 
predictor of PSC when compared to serum parameters alone (Hirche et al., 2004). 
 
 
Fig. 2. Screening for PSC in patients with IBD. Adapted from Navaneethan & Shen, 2010  
Rabinowitz et al., who investigated patients with advanced PSC ,  found that patients with 
PSC and UC are predominantly male and the first presentation is often mild liver enzyme 
elevation. Bile duct involvement is different among patients with PSC plus UC and those with 
PSC only. While the prevalence of combined  intrahepatic and extrahepatic bile duct strictures 
is 82%  in patients with PSC and UC, it is 46% in those with only PSC. Isolated extrahepatic 
duct involvement is 38% in PSC, and 7% in those with PSC and UC (Rabinovitz et al., 1990). 
Among 305 Swedish PSC patients, no difference between patients with and without IBD could 
be found (Broome et al., 1996). Currently, we do not have enough data to arrive at a conclusion 
that PSC in patients without IBD is an entity different from PSC that accompanies IBD. 
Rectal sparing and backwash ileitis are more common in patients with UC and PSC (Loftus 
et al., 2005). As rectal sparing is common in these patients, rectosigmoidoscopy is not 
Paents with IBD 
Non-specific symptoms fague/pruris and/or incidental abnormal liver funcon test 
Yes No 
Liver funcon tests Liver funcon test Q 1-6 months 
based on use of medicaons 
Normal 
Abnormal 
Hepatocellular Cholestac 
Addional lab evaluaon Ultrasound and/or MRCP 
Suspected small duct PSC 
Diagnosis of PSC 
Liver biopsy 
Liver mass 
Dominant 
stricture(s) 
ERCP with Cytology or Biopsy 
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adequate in demonstrating the association of UC and PSC, a colonoscopy is often 
recommended (Faubion et al., 2001; Perdigoto et al., 1991).  
The clinical course of colitis is variable in patients who undergo OLT for PSC. MacLean et al 
have reported clinical healing in one third of patients, unchanged clinical course in one 
third, and worsening in the last one third (MacLean et al., 2003).  
In UC patients operated on with an ileal pouch-anal anastomosis, nonspecific inflammation 
of the pouch (pouchitis) is the most frequent long-term complication. Chronic pouchitis is 
more common in patients with  PSC and UC when compared to those with UC only (60% vs 
15%)(Penna et al., 1996). Pouchitis continues to occur after OLT in patients with PSC (Zins BJ 
et al., 1995). 
3. Impact of coexisting PSC on the disease behavior and course of IBD 
Patients with PSC and IBD have a different clinical course when compared to IBD patients 
not complicated with PSC, and this patient group has been defined by the Mayo clinic as a 
different clinical entity (Loftus et al., 2005). While UC can be diagnosed many years after  
PSC diagnosis and even  after orthotopic liver transplantation(OLT), a patient with UC, who 
had a proctocolectomy or not, can be diagnosed with PSC many years later (Joo et al.,2009). 
Patients with UC and PSC more frequently experience rectal sparing, backwash ileitis, 
pancolitis, colorectal neoplasia when compared to patients with UC alone, and their 
prognosis is worse ( Faubion et al., 2001; Loftus et al., 2005; Loftus et al., 1997; Penna et al.; 
1996; Heuschen et al., 2001; Lundkvist & Broome, 1997; Broome et al., 1995; Soetikno et al., 
2002). However, there are studies reporting different results.  A recent case -control study 
found no difference between patients with PSC plus IBD and IBD alone in terms of rectal 
sparing. The same investigators found similar  backwash ileitis prevalences in the PSC plus 
UC group and the UC alone group (Joo et al., 2009). 
It was suggested that patients with PSC and UC may more likely run a quiescent course of 
colitis than UC patients without coexistent PSC. PSC-UC patients have colitis with a lower 
histopathological  grade of  inflammation (Joo et al.,2009). In a study from Sweden that 
included 76 patients with PSC, 7 of 11 asymptomatic patients had a histopathological 
diagnosis of IBD, and 2 of these 7 patients had colonic dysplasia. In the follow-up, these 2 
patients died before developing any IBD symptoms while 3 patients developed IBD 
symptoms (Broome et al.,1995). 
A colonoscopy must be performed at the time of PSC diagnosis for IBD screening (Faubion 
et al., 2001). Currently, there is no guideline about the necessity and frequency of 
colonoscopic screening in asymptomatic patients with a normal baseline screening 
colonoscopy. However, patients with PSC and UC/Crohn’s colitis should undergo annual 
colonoscopy (Kornbluth & Sachar,1997). 
The risk of pouchitis after restorative proctocolectomy is higher in patients with PSC and 
UC when compared to patients with UC alone ( Faubion et al.,2001; Loftus et al., 2005; 
Penna et al., 1996) . On the other hand, there is no correlation between the severity of liver 
disease and the risk of pouchitis (Penna et al., 1996). 
While there are conflicting reports in the literature, it is generally agreed upon that the risk 
of   IBD-associated colonic dysplasia is increased in the presence of PSC. In  a meta-analysis, 
the presence of PSC was an independent risk factor for colorectal dysplasia/cancer in UC 
patients with an odds ratio of  4.79 (Soetikno et al.,2002). Screening colonoscopy is 
associated with a survival benefit in patients with PSC and UC or Crohn’s colitis (Rutter et 
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al., 2004), and a yearly colonoscopy is recommended beginning from the time of  PSC 
diagnosis (Kornbluth & Sachar,1997).  The risk for dyplasia  seems to remain high after 
colectomy in patients with PSC and UC (Ståhlberg et al.,2003). According to histological and 
flow cytometry  studies,  atrophy in the pouch mucosa,  dysplasia, and DNA aneuploidia 
are more common in PSC plus UC patients with IPAA when compared to patients with UC 
only with IPAA (Ståhlberg et al.,2003). 
4. The impact of coexisting IBD on the disease behavior and course of PSC 
In a liver biopsy study that compared PSC patients with and without accompanying IBD  no 
difference was found in terms of liver histopathology (Ludwig et al.,1981). Two other 
studies  were unable to define any specific clinical or radiological criteria to distinguish 
patients with UC plus PSC from those with PSC alone (Broome et al., 1996; MacCarty et al., 
1985). On the other hand, Rabinovitz et al showed that the first sign of liver disease was 
often liver enzyme abnormality in PSC accompanied by IBD. In contrast, liver disease more 
often presented with jaundice, pruritus, and fatigue in patients with PSC alone (Rabinowitz 
et al., 1990). 
5. Pathogenesis 
As IBD tends to coexist with other autoimmune diseases  such as Type I diabetes mellitus 
and Graves’ disease (Saarinen S et al., 2000), genetic and immunological mechanisms have 
been extensively studied  (Navaneethan &  Shen, 2010). HLA-B8, HLA-DRB1*0301(DR3), 
HLA-DR3*0101(DRw52a), and HLA-DRB1*0401(DR4)  are among genetic variants that are 
associated with susceptibility to IBD (Farrant et al., 1992; Olerup et al., 1995). Many 
antibodies have been detected in PSC patients with varying prevalences, including 
antinuclear antibodies (24-53%), smooth muscle antibodies (13-20%), anti-perinuclear 
cytoplasmic antibody ( 65-88%) (Mulder et al., 1993; Bansi et al., 1996; Terjung & Spengler, 
2005; Terjung et al., 2000).  However, in contrast to other autoimmune diseases, PSC is more 
frequently encountered in male subjects, and it does not respond to immunosuppressive 
therapy (O’Mahony & Vierling, 2006). One hypothesis that aims to explain the increased 
incidence of PSC in IBD patients postulates that the transportation of bacterial endotoxins from 
the inflamed colonic mucosa to the liver via the portal circulation stimulates the Kupffer cells 
(Fausa et al., 1991; Aoki et al., 2005). However, another study showed that there is no evidence 
of altered intestinal permeability or bacterial overgrowth in PSC patients (Björnsson et 
al.,2000). Other factors that are suspected to play a role in pathogenesis are ANCA autoantigen 
Beta-tubulin isotype 5 (TBB5)  that shares epitopes with microbial antigens and human 
autoantigens (Erickson,1995) and  leaky gut (Terjung & Spengler,2009). 
6. Diagnosis 
Most PSC patients are asymptomatic at the time of diagnosis. Fatigue, pruritus, jaundice, 
abdominal pain, and weight loss are the presenting symptoms in 10-15% of the patients 
(Tischendorff et al., 2007; Wiesner et al., 1989). A cholestatic pattern of abnormal liver 
function tests in the form of elevation in alkaline phosphatase is a biochemical feature for 
PSC (Rasmussen HH et al., 1997; Talwalkar & Lindor, 2005).The most frequent cause of 
persistent liver enzyme elevation in a patient with IBD is PSC (Heikius et al., 1997). PSC is 
also the most frequent cause of persistent liver enzyme elevation in an IBD patient with 
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proctocolectomy (Navaneethan et al.,2009). Various antibodies may be detected with 
varying prevalences (antinuclear antibodies 24-53%, antismooth muscle antibodies 13-20%, 
p-ANCA 65-88%). Nevertheless,  the role of these antibodies in diagnosis and discrimination 
between isolated PSC and PSC accompanied by IBD remains unclear (Mulder et al., 1993; 
Bansi et al., 1996; Terjung & Spengler, 2005; Terjung et al., 2000). 
Diffuse, multifocal strictures involving the medium- sized intrahepatic and/or medium or 
large- sized extrahepatic ducts demonstrated by cholangiography constitutes the gold 
standard in the diagnosis of PSC (MacCarty et al.,1983) (Pictures 1 and 2). ERCP may be 
used both for diagnostic and therapeutic purposes, but is associated with procedure-related 
complications such as cholangitis and pancreatitis (Moreno & Gores, 2006). Magnetic 
Resonance  Cholangiopancreatography (MRCP) is a non-invasive alternative tool for PSC 
diagnosis. MRCP has a sensitivity of 80-91%, specifity of 85-99%, and diagnostic accuracy  of 
83-93% for diagnosis of PSC, all of which are slightly lower than those of ERCP (Fulcher et 
al., 2000; Angulo et al., 2000; Moff et al., 2006; Berstad et al., 2006; Textor et al., 2002).  
 
 
Picture 1. Percutaneus cholangiogram displaying early PSC in a 45-year-old man with 
ulcerative colitis and elevated results of liver function tests. (Vitellas et al., 2000) 
Liver biopsy is useful for the diagnosis of small-duct PSC or pericholangitis in IBD patients 
with cholestatic enzyme elevation and a normal cholangiogram (Burak et al., 2003). US 
examination of the liver may be used for screening in patients with liver enzyme elevation. 
The demonstration of dilated bile ducts by US may guide the clinician for further 
evaluations such as  ERCP or liver biopsy. Nevertheless, there is no published data about 
the value of abdominal US for screening purposes in PSC (Navaneethan U, Shen B, 2010). 
Another clinical scenario that may be encountered throughout the clinical course of PSC is 
cholangiocarcinoma ( Picture 3) .Current imaging methods have limited capability in the 
early diagnosis of cholangiocarcinoma and most patients are diagnosed at advanced stages 
of the disease.  Computerized tomography (CT) and magnetic resonance imaging (MRI) 
have higher sensitivity than US, but US examination may provide better accuracy than CT and 
MRI in distinguishing cholangiocarcinoma from underlying PSC (Charatcharoenwitthaya et 
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al., 2008). When a mass lesion is detected by US ,CT or MRI may be performed to assess the 
extent of the mass.  
 
 
Picture 2. Percutaneus cholangiogram displaying PSC in a 67-year-old man with ulcerative 
colitis and jaundice. (Vitellas et al., 2000)  
 
 
Picture 3. MRCP image of cholangiocarcinoma in a 29-year-old man with ulcerative colitis 
and primary sclerosing cholangitis who presented with jaundice and abdominal pain. 
(Vitellas et al., 2000) 
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ERCP with brush cytology or CT/ US guided biopsy of the mass may be required to 
accurately establish the diagnosis. ERCP is especially useful for the final diagnosis of 
cholangiocarcinoma, as it provides opportunities such as brush cytology and obtaining a 
biopsy sample (Charatcharoenwitthaya et al.,2008 ). The application of advanced cytological 
techniques such as  digital imaging analysis (DIA) and fluorescent in situ hybridization 
(FISH) in brush cytology and biopsy samples obtained by ERCP may further facilitate the 
early diagnosis of cholangiocarcinoma (Moreno & Gores, 2006; Rea et al., 2005; Parsi et al., 
2008). The sensitivity of combined use of cytology, FISH and DIA is 50-64%, spesicifity and 
positive predictive value is 100% (Charatcharoenwitthaya et al.,2008 ). The National 
Institutes of Health consensus statement on the role of diagnostic and therapeutic ERCP 
described the role of ERCP in the diagnosis of biliary cancers in patients with PSC (Cohen et 
al.,2002 ). It is not clear whether a different surveilliance program is needed in case PSC is 
accompanied by IBD. An algorithm for cholangiocarcinoma screening in patients with IBD 
and PSC is given below (Figure 3). The advantages and disadvantages of diagnostic 
modalities are  summarized in Table 4. 
 
 
Fig. 3. Surveilliance of cholangiocarcinoma in patients with IBD-PSC  
(Adapted from Charatcharoenwitthaya P and Lindor KD, 2007) 
Diagnosis of PSC 
Annual liver 
funcon tests, 
CA19-9 and US 
Biliary 
ductal 
dilataon 
Liver mass 
Persistent high CA19-9, 
radiologic findings of biliary 
tumor 
CT/MRI Abdomen 
MRCP 
ERCP/PTC 
with ssue 
sampling 
EUS/CT 
guided 
ssue 
sampling 
Metastasis 
from 
primary site 
Work up 
depending 
on the 
primary 
Cholangiocarcinoma No cholangiocarcinoma 
Repeat ERCP/CT abdomen in 3-6 
months 
Intrahepac 
Extrahepac 
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Diagnostic modality Advantages Disadvantages 
Endoscopic retrograde 
cholangiopancreatography(ERCP) 
-Can be both diagnostic 
and therapeutic 
Gold standart for 
diagnosis of PSC 
-Complications, 
including post-ERCP 
pancreatitis. 
-Procedure associated 
cholangitis 
Magnetic resonance retrograde 
cholangiopancreatography 
(MRCP) 
-Visualizing bile ducts 
proximal to a complete 
bile duct obstruction 
-Useful in patients with 
gastric bypass or biliary-
enteric anastomosis 
without radiation 
exposure 
-Purely diagnostic 
-PSC limited to the 
peripheral ducts 
-Sensitivity and 
specificity slightly 
inferior to ERCP 
Liver biopsy -Diagnosis of small duct 
PSC in suspected 
patients with a normal 
cholangiography 
-Patchy nature of PSC 
which leads to 
sampling error 
Abdominal ultrasound Screening for biliary 
ductal dilatation 
Insensitive for 
diagnosis of PSC 
Table 4. Diagnostic modalities in primary sclerosing cholangitis  
(Adapted from Navaneethan & Shen 2010) 
7. Natural history 
Both symptomatic and asymptomatic PSC patients have decreased survival rates when 
compared to healthy population (Porayko et al., 1990). Median survival from time of 
diagnosis to death or liver transplantation was reported as 10 years (Farrant et al., 1991).  
In a Dutch cohort, transplantation free survival was 18 years on average (Ponsioen et 
al.,2002 ). PSC patients are prone to end stage liver disease complications such as esophageal 
varices, ascites, and hepatic encephalopathy. There are no guidelines on timing of screening 
for esophageal varices in PSC with or without IBD except for patients with cirrhosis. 
Because of the patchy nature of PSC, liver biopsy is limited by sampling error. Thus, non-
invasive diagnostic methods were explored.  A platelet count less than  150000/mm3  may 
be a  marker for the presence of  esophageal varices (Zein et al.,2004 ).  The composite Mayo 
Risk Score based on age, serum bilirubin, albumin, aspartate aminotransferase and  variceal 
bleeding has been used to assess disease progression and prognosis (Kim et al., 2000). 
Cholangiocarcinoma is another complication of PSC and annual incidence is 0.6%-
1%(Bergquist el al., 2007). It can develop at any stage of PSC, it can present as an intraductal 
tumor in the biliary system or rarely as a hepatic mass (Fevery et al.,2007). The risks of 
colorectal cancer and pancreatic cancer are also increased in patients with PSC when 
compared to the general population (Kim et al., 2000 ). 
8. Management 
The presence of accompanying IBD does not change the therapeutic approach in patients 
with PSC. Currently, there is no treatment option capable of halting progression to PSC or 
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modifying the natural course of the disease. Ursodeoxycholic acid (UDCA) is widely used 
for the treatment of PSC. A randomized trial which tested a UDCA dose of 13-15 
mg/kg/day showed normalization in liver enzyme levels, however, there was no 
improvement of liver histology or liver transplant free survival (Lindor,1997). In another 
randomized trial that included 219 patients, a higher dosage of UDCA treatment  (17-23 
mg/kg/day) did not result in any benefit in terms of mortality, need for OLT, or 
cholangiocarcinoma risk (Olsson, 2005).  A pilot study reported that a very high dosage of 
UDCA (28-30 mg/kg/day) might improve survival (Cullen et al., 2008) ,however,  a large 
multicenter randomized controlled trial was terminated prematurely due to side effects in 
the treatment arm (Lindor et al., 2009).  
UDCA treatment can prevent colonic neoplasia in PSC-IBD patients (Tung et al., 2001). On 
the other hand, high dose UDCA treatment was reported to increase the risk of colon cancer 
in PSC-UC patients (Eaton et al., 2011). 
The treatment of choice in end stage PSC or cholangiocarcinoma-PSC is OLT. The 5 and 10 
year survival rates in PSC patients are 85% and 70%, repectively (Rea et al., 2005 and 
Graziadei et al., 1999a).  On the other hand, the rate of PSC recurrence in the transplanted 
liver is 20%-25% (Graziadei et al., 1999b). 
Small-duct PSC: This entity was previously termed pericholangitis. These patients have 
biochemical and histopathological features compatible with PSC despite normal 
cholangiograms (Wee et al., 1985). The Mayo Clinic’s criteria for  the diagnosis of small-duct 
PSC mandates the presence of coexisting IBD (Angulo et al., 2002). On the other hand, 
European criteria for small duct PSC does not include the presence of IBD (Björnsson et al., 
2002 and, Broome et al., 2002). Initial studies with limited follow-up suggested that patients 
with small-duct PSC have a better prognosis than those with its large-duct counterpart 
(Angulo P et al., 2002; Björnsson et al., 2002 and, Broome et al., 2002). A large multicenter 
study with a longer follow-up period showed that the incidence of IBD is 80% in patients  
with small-duct PSC. Accompanying IBD was UC in 78%, Crohn’s colitis in 21%, and  
collagenous colitis in one patient (Björnsson et al., 2008). 
The presence of IBD does not seem to have an effect on the course of liver disease in patients 
with small-duct PSC. 12-23% of patients with small-duct PSC progress to large-duct PSC. 
Cholangiocarcinoma developing in the setting of isolated small-duct PSC has never been 
reported in the literature, unless it progresses to large-duct PSC (Björnsson et al., 2008). In 
some patients, OLT may be necessary because of progressive disease and disease recurrence 
may be encountered in the transplanted liver.  If the alkalene phosphatase level is elevated, 
cholangiogram is normal, and other hepatobiliary diseases are ruled out in an IBD  patient, 
liver biopsy may be required to rule out small-duct PSC (Navaneethan & Shen, 2010). 
9. Disease course of IBD following liver transplantation for PSC 
OLT for PSC or PSC-associated cholangiocarcinoma may affect the clinical course of UC, as 
corticosteriods and other immunosuppressive agents used following OLT may theoretically 
improve coexisting UC. However, while some studies report alleviation of UC-associated 
symptoms after OLT (Saldeen et al., 1999 and Befeler et al., 1998) , some studies report 
exacerbation of symptoms after OLT (Riley et al., 1997; Papatheodoridis et al., 1998 and 
Verdonk et al., 2006). 
The effect of OLT on the natural course of ileal pouch in UC patients undergoing restorative 
proctocolectomy seems to be minor. In some case series, OLT and subsequent 
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immunosuppressive therapy did not have a significant effect on the severity of pouchitis  
(Zins BJ et al.,1995). In a recent study investigating  the modification of chronic pouchitis 
course by PSC and/or OLT performed for PSC, 14 of 32 patients who underwent both IPAA 
and OLT for PSC experienced chronic pouchitis and in 8 patients PSC recurred, with 4 of 
them requiring retransplantation (Mathis et al., 2008). Large scale studies are needed to 
clarify the disease nature of pouchitis and the interaction of it with OLT and OLT related 
procedures. 
10. Course of liver disease following IPAA 
IPAA does not appear to affect the disease course of PSC and PSC appears to follow an 
independent disease course in spite of proctocolectomy (Poritz & Koltun, 2003). In a study 
of 214 patients with UC undergoing IPAA including 13 (6.1%) with PSC, 4 patients with PSC 
showed clinical progression, while none of these patients with minor histological changes 
progressed with a follow-up over 9 years (Mikkola et al., 1995). In a study of PSC in 68 
patients with UC with 30 having follow-up examinations, the staging of PSC on liver biopsy 
after IPAA showed disease progression in 4 (13%), regression in 15 (50%), and stable in 11 
(37%) from baseline liver histology at the time of proctocolectomy. Six of the 68 patients 
(8.8%) developed cholangiocarcinoma. The progression of PSC in patients with minor ductal 
changes appeared to be uncommon after IPAA surgery (Lepistö et al., 2009).  
11. Colorectal Dysplasia and carcinoma in patients with Ulcerative Colitis and 
Primary Sclerosing Cholangitis 
It is well-known that the risk of developing colorectal carcinoma is increased in patients 
with UC. Disease duration and extensive colitis are two major risk factors for this serious 
complication. The mechanism of developing malignancy in UC is not fully understood. 
Recent studies have shown that family history of sporadic colorectal carcinoma (Askling et 
al., 2001), presence of active inflammation in the mucosa (Rutter et al., 2004), and presence of 
PSC increase the risk of dysplasia and colorectal carcinoma in patients with UC (Kornfeld et 
al., 1997; Brentnall et al., 1996). A study from Sweden has shown that the incidence of 
colorectal dysplasia and carcinoma in patients with UC and PSC at 10, 20, and 25 years is 
9%, 31% and 50% respectively (Broome et al., 1995). A meta-analysis of 11 studies has shown 
that the presence of PSC is an independent risk factor for colorectal dysplasia/carcinoma in 
patients with UC (Soetikno et al.,2002).  
The incidence of colorectal dysplasia/cancer is high after orthotopic liver transplantation 
(OLT) in patients with UC and PSC (Bleday et al., 1993; Higashi et al., 1990). The risk of 
developing colorectal carcinoma increases over time after OLT.  Vera et al. have identified 
three risk factors for developing colorectal carcinoma after OLT; colitis duration of more 
than 10 years, pancolitis, and dysplasia after OLT (Vera et al., 2003).  A yearly colonoscopy 
is adequate in patients with PSC and UC, beginning from the time of PSC diagnosis 
(Broome & Bergquist, 2006). 
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